Chief Commercial Officer
Tony Gustavsson leads the licensing and commercialization efforts of the company’s lead drug candidate arfolitixorin. Prior to joining Isofol, Mr. Gustavsson served in increasingly senior commercial positions in AstraZeneca and its predecessor companies. During his career Mr. Gustavsson has worked in local, regional and global commercial roles based in Sweden, the UK and the US. Most recently Mr. Gustavsson was the global head of the Pricing and Market Access department responsible for AstraZeneca’s Cardiovascular, Metabolic and Renal portfolio. Prior to this role he was the global Commercial Lead for one of AstraZeneca’s antidiabetics franchises leading the global launch of the products. Mr Gustavsson has an BSc in Business, Administration and Economics from Lund University.
Tony joined Isofol in 2020.
Position: Chief Commercial Officer
Holdings: 0 shares*, 117 534 warrants**
E-mail: tony.gustavsson@isofolmedical.com
–*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of September 30, 2020.
** Isofol Medical AB (publ) warrent program 2018 series 2018/2022 and 2018/2023 . For more information and terms read more under Corporate Governance.